Farglitazar
From Self-sufficiency
Revision as of 06:46, 21 July 2010 by Citation bot 1 (Talk) (Citations: [Pu177]Tweaked: issue, pmid. You can use this bot yourself! Report bugs here.)
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (February 2009) |
| File:Farglitazar.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
N-(o-benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine | |
| Identifiers | |
| CAS Number | 196808-45-4 |
| ATC code | none |
| PubChem | CID 170364 |
| Chemical data | |
| Formula | C34H30N2O5 |
| Molar mass | 546.612 g/mol[[Script error: No such module "String".]] |
Farglitazar is a is a peroxisome proliferator-activated receptor agonist which is being developed by GlaxoSmithKline for the treatment of hepatic fibrosis. It is currently in phase II clinical trials.
Henke, Brad R.; Blanchard, Steven G.; Brackeen, Marcus F.; Brown, Kathleen K.; Cobb, Jeff E.; Collins, Jon L.; Harrington,, W. Wallace; Hashim, Mir A.; Hull-Ryde, Emily A. (1998). "N-(2-Benzoylphenyl)-l-tyrosine PPARγ Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents". Journal of Medicinal Chemistry. 41 (25): 5020. doi:10.1021/jm9804127. PMID 9836620.
Categories:
- Pages with script errors
- Pages with broken file links
- Orphaned articles from February 2009
- Articles with invalid date parameter in template
- All orphaned articles
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
